The similarities between CytRx and Pharmacyclics are hard to ignore. A world class platform that has the potential to cure millions and generate billions, a significant institutional interest, and a rapid share price explosion, all lend credence to the theory that CytRx may soon follow a similar path to Pharmacyclics.
In the opening paragraph, I suggested that CytRx may be on pace to become the next Pharmacyclics. There are several reasons why I think this may be the case:
Platform applicable to multiple diseases
“Smart Money” purchasing shares
Sudden share price explosion
World Class Platform
The biggest reason why I am comparing CytRx to Pharmacyclics is because of the ability to apply its treatment to multiple diseases. Pharmacyclics’ rise came mainly because of IMBRUVICA, a BtK inhibitor. BTK is a signaling protein that is critically important for the activity of B-cells (immune cells that produce antibodies to help fight infection). Targeted inhibition of BTK is a novel approach for treating many different human diseases associated with the inappropriate activation of B-cells, including B-cell malignancies (cancers such as certain forms of lymphoma, leukemia, and multiple myeloma) and potentially autoimmune and inflammatory disorders (such as rheumatoid arthritis). In fact, Pharmacyclics is currently evaluating IMBRUVICA for treatment of the following diseases:
With this week’s press release, it appears that CytRx may be developing a world-class platform as well. It is currently evaluating aldoxorubicin in 4 major diseases with the potential to pursue further treatments down the road. Based on the outstanding data shown in the Phase 2b trial, I wouldn’t be surprised at all to see the company start to consider trials in additional types of cancer